Abstract：
OBJECTIVE: Thymoma is a rare tumour. The most common treatment for thymoma is surgical resection, while the use of radiotherapy and chemotherapy remains controversial.
METHODS: We conducted a monocentric observational study of 31 patients diagnosed with thymoma from June 2004 to July 2020 at cancer centre in Strasbourg, France. We analysed the outcomes of the patients.
RESULTS: The 2- and 5- year locoregional relapse-free survival rates were 96.3% (95% confidence interval [CI]: 76.5-99.5%) and 68.0% (95% CI: 43.8-83.5%), respectively. Radiotherapy and chemotherapy significantly improved local tumour control (P=0.0008 and 0.04, respectively), while a larger initial tumour size significantly worsened local control rates (P=0.04). The 5- and 10-year overall survival rates were 87.1% (95% CI: 69.2-95%) and 81.7% (95% CI: 60.3-92.2%), respectively. The median overall survival was not reached, and no favourable factor was retrieved. For relapsed patients, the median overall survival after relapse was 115 months.
CONCLUSIONS: Despite the inherent limitations of retrospective studies with a limited patient sample size, we demonstrated that chemotherapy and radiotherapy in addition to surgery were effective in achieving local control and contributed to improving patient outcomes in thymoma. Notably, an aggressive treatment strategy at the time of relapse resulted in favourable outcomes for retreated patients.
METHODS: We conducted a monocentric observational study of 31 patients diagnosed with thymoma from June 2004 to July 2020 at cancer centre in Strasbourg, France. We analysed the outcomes of the patients.
RESULTS: The 2- and 5- year locoregional relapse-free survival rates were 96.3% (95% confidence interval [CI]: 76.5-99.5%) and 68.0% (95% CI: 43.8-83.5%), respectively. Radiotherapy and chemotherapy significantly improved local tumour control (P=0.0008 and 0.04, respectively), while a larger initial tumour size significantly worsened local control rates (P=0.04). The 5- and 10-year overall survival rates were 87.1% (95% CI: 69.2-95%) and 81.7% (95% CI: 60.3-92.2%), respectively. The median overall survival was not reached, and no favourable factor was retrieved. For relapsed patients, the median overall survival after relapse was 115 months.
CONCLUSIONS: Despite the inherent limitations of retrospective studies with a limited patient sample size, we demonstrated that chemotherapy and radiotherapy in addition to surgery were effective in achieving local control and contributed to improving patient outcomes in thymoma. Notably, an aggressive treatment strategy at the time of relapse resulted in favourable outcomes for retreated patients.
摘要：
目的：胸腺瘤是一种罕见的肿瘤。胸腺瘤最常见的治疗方法是手术切除，而放疗和化疗的使用仍然存在争议。
方法：我们在2004年6月至2020年7月在斯特拉斯堡的癌症中心对31名诊断为胸腺瘤的患者进行了单中心观察研究。法国。我们分析了患者的结果。
结果：2年和5年无局部复发生存率分别为96.3%（95%置信区间[CI]：76.5-99.5%）和68.0%（95%CI：43.8-83.5%），分别。放疗和化疗显著改善了局部肿瘤控制（P分别为0.0008和0.04）。而较大的初始肿瘤大小显着恶化了局部控制率（P=0.04）。5年和10年总生存率分别为87.1%（95%CI：69.2-95%）和81.7%（95%CI：60.3-92.2%），分别。未达到中位总生存期，没有找到有利因素。对于复发的患者，复发后的中位总生存期为115个月.
结论：尽管患者样本量有限的回顾性研究存在固有的局限性，我们证明,除手术外,化疗和放疗可有效实现局部控制,并有助于改善胸腺瘤患者的预后.值得注意的是,在复发时采用积极的治疗策略对复治患者产生了良好的结局.
方法：我们在2004年6月至2020年7月在斯特拉斯堡的癌症中心对31名诊断为胸腺瘤的患者进行了单中心观察研究。法国。我们分析了患者的结果。
结果：2年和5年无局部复发生存率分别为96.3%（95%置信区间[CI]：76.5-99.5%）和68.0%（95%CI：43.8-83.5%），分别。放疗和化疗显著改善了局部肿瘤控制（P分别为0.0008和0.04）。而较大的初始肿瘤大小显着恶化了局部控制率（P=0.04）。5年和10年总生存率分别为87.1%（95%CI：69.2-95%）和81.7%（95%CI：60.3-92.2%），分别。未达到中位总生存期，没有找到有利因素。对于复发的患者，复发后的中位总生存期为115个月.
结论：尽管患者样本量有限的回顾性研究存在固有的局限性，我们证明,除手术外,化疗和放疗可有效实现局部控制,并有助于改善胸腺瘤患者的预后.值得注意的是,在复发时采用积极的治疗策略对复治患者产生了良好的结局.
